Sodium Oligomannate: New Alzheimers Drug Approved In China

High_Prob

Member
Joined
Mar 23, 2016
Messages
391
China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years
https://www.cnn.com/2019/11/03/health/china-alzheimers-drug-intl-hnk-scli/index.html



Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression

OpenAthens / Sign in

Abstract


Recently, increasing evidence has suggested the association between gut dysbiosis and Alzheimer’s disease (AD) progression, yet the role of gut microbiota in AD pathogenesis remains obscure. Herein, we provide a potential mechanistic link between gut microbiota dysbiosis and neuroinflammation in AD progression. Using AD mouse models, we discovered that, during AD progression, the alteration of gut microbiota composition leads to the peripheral accumulation of phenylalanine and isoleucine, which stimulates the differentiation and proliferation of pro-inflammatory T helper 1 (Th1) cells. The brain-infiltrated peripheral Th1 immune cells are associated with the M1 microglia activation, contributing to AD-associated neuroinflammation. Importantly, the elevation of phenylalanine and isoleucine concentrations and the increase of Th1 cell frequency in the blood were also observed in two small independent cohorts of patients with mild cognitive impairment (MCI) due to AD. Furthermore, GV-971, a sodium oligomannate that has demonstrated solid and consistent cognition improvement in a phase 3 clinical trial in China, suppresses gut dysbiosis and the associated phenylalanine/isoleucine accumulation, harnesses neuroinflammation and reverses the cognition impairment. Together, our findings highlight the role of gut dysbiosis-promoted neuroinflammation in AD progression and suggest a novel strategy for AD therapy by remodelling the gut microbiota.

Introduction
Despite the tremendous efforts made in the treatment of Alzheimer’s disease (AD), the past decades have witnessed the continuous failure of β-amyloid (Aβ)- or tau-centric therapeutic strategies in late-stage clinical trials, which impels the reconsideration of new therapeutic strategy for this complicated disease.1,2 Recently, a plethora of studies have shown the dynamic interaction between the intestinal microbiota and host innate and adaptive immune system.3,4 The dysbiosis of gut microbiota could jeopardize host immune responses and promote the development of various inflammatory disorders.5 This also appears to be the case for AD-associated inflammation. Emerging evidence from both animal and human studies supports the association between dysbiosis of the gut microbiota and the microglia activation during AD development.6,7,8 For example, Minter et al. discovered that perturbations in gut microbial diversity influenced neuro-inflammation and amyloidosis. Antibiotics-treated mice showed a significant decrease in plaque-localized microglial activation positive for IBA-1.9 Besides, gut microbiota-produced lipopolysaccharide (LPS) was found in the post-mortem brain samples of AD patients,10 and peripheral injection of LPS could promote microglial activation.11,12 All the evidence suggests that gut microbiota is likely involved in regulating microglia activation and neuroinflammation in AD.
 

Similar threads

Back
Top Bottom